Alkermes Past Earnings Performance

Past criteria checks 3/6

Alkermes has been growing earnings at an average annual rate of 51.8%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 5.9% per year. Alkermes's return on equity is 43.2%, and it has net margins of 31.2%.

Key information

51.8%

Earnings growth rate

51.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate5.9%
Return on equity43.2%
Net Margin31.2%
Last Earnings Update31 Dec 2023

Recent past performance updates

Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point

Nov 01
Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point

Recent updates

Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet

Jan 26

Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?

Nov 01
Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?

Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point

Nov 01
Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point

Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?

Jul 15
Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?

There Is A Reason Alkermes plc's (NASDAQ:ALKS) Price Is Undemanding

Jun 07
There Is A Reason Alkermes plc's (NASDAQ:ALKS) Price Is Undemanding

Is Alkermes plc (NASDAQ:ALKS) Trading At A 44% Discount?

Apr 10
Is Alkermes plc (NASDAQ:ALKS) Trading At A 44% Discount?

Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Mar 20
Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Alkermes upgraded to neutral at BofA on improved risk/reward outlook

Oct 14

Alkermes holder Sarissa Capital says it may look to increase its stake

Oct 07

Alkermes: Nothing Stands Out As Interesting

Sep 26

Health Check: How Prudently Does Alkermes (NASDAQ:ALKS) Use Debt?

Aug 29
Health Check: How Prudently Does Alkermes (NASDAQ:ALKS) Use Debt?

Alkermes initiated at neutral at Piper Sandler as company in transition

Aug 16

Alkermes Q2 2022 Earnings Preview

Jul 26

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 44% Undervaluation?

Jun 27
Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 44% Undervaluation?

Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

May 16
Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

Alkermes: Turning The Tides Towards Profitability

Apr 16

Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

Feb 07
Alkermes (NASDAQ:ALKS) Has Debt But No Earnings; Should You Worry?

Alkermes plc's (NASDAQ:ALKS) Intrinsic Value Is Potentially 100% Above Its Share Price

Jan 12
Alkermes plc's (NASDAQ:ALKS) Intrinsic Value Is Potentially 100% Above Its Share Price

Is Alkermes (NASDAQ:ALKS) Weighed On By Its Debt Load?

Oct 24
Is Alkermes (NASDAQ:ALKS) Weighed On By Its Debt Load?

Revenue & Expenses Breakdown
Beta

How Alkermes makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:ALKS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,663519701254
30 Sep 231,591215723374
30 Jun 231,462103708381
31 Mar 231,121-164653374
31 Dec 221,112-33603260
30 Sep 221,132-129627370
30 Jun 221,173-94610387
31 Mar 221,201-62600391
31 Dec 211,17476550291
30 Sep 211,129-92566401
30 Jun 211,100-63558376
31 Mar 211,044-95551373
31 Dec 201,039-111539395
30 Sep 201,171-74566462
30 Jun 201,162-126585477
31 Mar 201,194-139606489
31 Dec 191,171-197599513
30 Sep 191,074-201598412
30 Jun 191,067-183578406
31 Mar 191,092-173561409
31 Dec 181,094-139537415
30 Sep 181,054-139507410
30 Jun 181,023-141477414
31 Mar 18937-152448406
31 Dec 17903-158422413
30 Sep 17842-169417389
30 Jun 17804-196408384
31 Mar 17781-200395382
31 Dec 16746-208383378
30 Sep 16695-257373382
30 Jun 16668-275372376
31 Mar 16624-274347367
31 Dec 15628-227320336
30 Sep 15640-127287317
30 Jun 15648-86249303
31 Mar 15650-36228283
31 Dec 14619-30207265
30 Sep 14598-42201235
30 Jun 14578-10189202
31 Mar 14563-7168172
31 Dec 1359621162153
30 Sep 1357819144140
30 Jun 1356210135130
31 Mar 1357625131135

Quality Earnings: ALKS has a high level of non-cash earnings.

Growing Profit Margin: ALKS became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ALKS has become profitable over the past 5 years, growing earnings by 51.8% per year.

Accelerating Growth: ALKS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ALKS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: ALKS's Return on Equity (43.2%) is considered outstanding.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.